Invention Grant
- Patent Title: Serum albumin-binding fibronectin type III domains
-
Application No.: US15611296Application Date: 2017-06-01
-
Publication No.: US10925932B2Publication Date: 2021-02-23
- Inventor: Michael Diem , Steven Jacobs , Karyn O'Neil , Thomas Rutkoski
- Applicant: Janssen Biotech, Inc.
- Applicant Address: US PA Horsham
- Assignee: Janssen Biotech, Inc.
- Current Assignee: Janssen Biotech, Inc.
- Current Assignee Address: US PA Horsham
- Agency: Ice Miller LLP
- Main IPC: C07K14/78
- IPC: C07K14/78 ; A61K38/39 ; A61K47/54 ; C07K16/18 ; C07K16/40 ; A61K39/00

Abstract:
Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
Public/Granted literature
- US20170348397A1 Serum Albumin-Binding Fibronectin Type III Domains Public/Granted day:2017-12-07
Information query